1. Field of the Invention
The present invention relates generally to a device for attaching a first mass to a second mass and methods of making and using the same.
2. Description of the Prior Art
Prosthetic heart valves can replace defective human valves in patients. Prosthetic valves commonly include sewing rings, suture cuffs or rings that are attached to and extend around the outer circumference of the prosthetic valve orifice.
In a typical prosthetic valve implantation procedure, the aorta is incised and the defective valve is removed leaving the desired placement site that may include a fibrous tissue layer or annular tissue. Known heart valve replacement techniques include individually passing sutures through the fibrous tissue or desired placements site within the valve annulus to form an array of sutures. Free ends of the sutures are extended out of the thoracic cavity and laid, spaced apart, on the patient's body. The free ends of the sutures are then individually threaded through a flange of the sewing ring. Once all sutures have been run through the sewing ring (typically 12 to 18 sutures), all the sutures are pulled up taught and the prosthetic valve is slid or “parachuted” down into place adjacent the placement site tissue. The prosthetic valve is then secured in place by traditional knot tying with the sutures. This procedure is time consuming as doctors often use three to ten knots per suture.
The sewing ring is often made of a biocompatible fabric through which a needle and suture can pass. The prosthetic valves are typically attached to the sewing rings which are sutured to a biological mass that is left when the surgeon removes the existing valve from the patient's heart. The sutures are tied snugly, thereby securing the sewing ring to the biological mass and, in turn, the prosthetic valve to the heart.
During heart valve replacement procedures, the patient is on heart-lung bypass which reduces the patient's oxygen level and creates non-physiological bloodflow dynamics. The longer a patient is on heat-lung bypass, the greater the risk for permanent health damage. Existing suturing techniques extend the duration of bypass and increase the health risks due to heart-lung bypass. Furthermore, the fixturing force created by suturing varies significantly from suture to suture, even for the same medical professional.
In addition, sutures and other attachment devices are used in a variety of medical applications where the use of the device of the present invention would provide an advantage in fixing a first mass to a second mass, where the first mass is a tissue or a device or prosthesis, and the second mass is a tissue or a device or prosthesis. These applications include anchoring a prosthesis such as a synthetic or autologous graft to surrounding tissue or another prosthesis, tissue repair such as in the closure of congenital defects such as septal heart defects, tissue or vessel anastomosis, fixation of tissue with or without a reinforcing mesh for hernia repair, orthopedic anchoring such as in bone fusing or tendon or muscle repair, ophthalmic indications, laparoscopic or endoscopic tissue repair or placement of prostheses, or use by robotic devices for procedures performed remotely.
For these indications and others, there is a need for a fixturing device to minimize the time spent fixturing certain devices or conduits, such as a valve prosthesis and a second mass, a vessel to another vessel or anatomical structure, tissue to tissue, surrounding tissue to a second prosthesis, and the like as described above. Furthermore, there is a need for a device that compliments existing suturing or attachment devices and methods and reduces fixturing times. Also, there is a need for a fixturing device that can be easily removed. There also exist a need to provide a fixturing device that can provide a consistent fixturing force.
A device for connecting a first mass to a second mass is disclosed. The device has a base and a first leg. The base has a base axis, a first end and a second end. The first leg extends from the first end of the base. The device has a first configuration and a second configuration. When the base is rotated with respect to the base axis, the device is in the first configuration. The device can also have a second leg extending from the second end of the base.
Another device for connecting a first mass to a second mass is disclosed. The device has a base, a first leg and a second leg. The base has a base axis, a first end and a second end. The first leg has a first longitudinal axis and a first leg length. The first leg extends from the first end of the base. The second leg has a second longitudinal axis and a second leg length. The second leg extends from the second end of the base. The first leg length is substantially longer than the second leg length.
The device can have a first configuration and a second configuration. When the base is rotated with respect to the base axis, the device is in the first configuration.
Yet another device for connecting a first mass to a second mass is disclosed. The device has a base, a first leg and a second leg. The base is curved. The base has a base diameter, a first end and a second end. The first leg has a first longitudinal axis and a first leg length. The first leg extends from the first end of the base. The second leg has a second longitudinal axis and a second leg length. The second leg extends from the second end of the base. The device has a relaxed configuration. In the relaxed configuration the first leg crosses the second leg at a leg angle. The leg angle is less than 180 degrees.
The leg angle can be less than or equal to 90 degrees. The leg angle can be less than or equal to 60 degrees. The base diameter can be less than or equal to 0.13 inches. The base diameter can be greater than or equal to 0.08 inches.
A method of attaching a first mass to a second mass is disclosed. The method uses an attachment device having a base, a first leg, and a second leg. The base has a first end and a second end. The first leg extends from the first end of the base. The second leg extends from the second end of the base. The attachment device has a first configuration and a second configuration. The method includes holding the attachment device in the first configuration. The method also includes twisting the base of the attachment device to force the attachment device into the second configuration. Further, the method includes inserting the attachment device into the first mass and the second mass. The method also includes releasing the attachment device.
Twisting the base of the attachment device can occur before inserting the attachment device into the first mass. Inserting the attachment device, at least partially, into the first mass can occur before twisting the base of the attachment device.
Another method of attaching a first mass to a second mass is disclosed. The method includes forcibly holding an attachment device in a second configuration. The attachment device has a first configuration and the second configuration. The method also includes inserting the attachment device into the first mass and the second mass. The method also includes releasing the attachment device into the first configuration.
The attachment device 2 can be made from a deformable or elastic material or a combination of materials having resulting deformable or elastic properties. The material can be, for example, stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CONICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), polymers such as polyester (e.g., DACRON® from E.I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ether ketone (PEEK), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Mass.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), extruded collagen, silicone, echogenic, radioactive, radiopaque materials or combinations thereof. Examples of radiopaque materials are barium sulfate, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
Any or all elements of the attachment device 2 can be a matrix for cell ingrowth or used with a fabric, for example a covering (not shown) that acts as a matrix for cell ingrowth. The fabric can be, for example, polyester (e.g., DACRON® from E.I. du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, nylon, extruded collagen, silicone or combinations thereof.
The attachment device 2 and/or the fabric can be filled and/or coated with an agent delivery matrix known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. These agents can include radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; mefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J. Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J. Surgery 86 (6), 771-775; Xu et al, Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
A base axis 12 can extend longitudinally through the transverse cross-sectional center of the base 4. As shown in
The base 4 and legs 6 can have a shaft diameter 18 from about 0.03 mm (0.001 in.) to about 6.35 mm (0.250 in.), for example, about 0.51 mm (0.020 in.). The base 4 and legs 6 can have the same or different shaft diameters 18. A base neutral radius 19 can be the base inner radius 16 and half the shaft diameter 18. As shown in
The length from an end of the base 4 to a longitudinal leg axis 24 can be a body length 22. The body length 22 can be from about 0.25 mm (0.010 in.) to about 12.7 mm (0.500 in.), for example about 2.913 mm (0.1147 in.). The length between the distal end of one tip 8 and the distal end of the opposite tip 8 can be a tip distance 26. The tip distance 26 can be from about 0.03 mm (0.001 in.) to about 25.4 mm (1.000 in.), more narrowly about 1.3 mm (0.050 in.) to about 3.18 mm (0.125 in.), for example about 2.3 mm (0.090 in.).
The tip 8 can have a tip length 28 from about 0.05 mm (0.002 in.) to about 12.7 mm (0.500 in.), for example about 1.0 mm (0.040 in.). The tip 8 can have a tip angle 30 from about 50 to about 90°, for example about 30°. The tips 8 can be straight, pointed ends, curve out of line (shown by alternative tips 8a and 8b, drawn in phantom lines in
The tips 8 and/or legs 6 can have retention devices 29. The retention devices 29 can be barbs, spikes, hooks, threads, ribs, splines, a roughened surface, a sintered surface, a covered surface (e.g., with DACRON® from E.I. du Pont de Nemours and Company, Wilmington, Del.) or combinations thereof. A retention coating 31, for example a biodegradable coating or filler such as gel or gelatin or otherwise removable, can be on and/or around and/or near the retention devices 29. The retention coating 31 (shown in phantom lines) can be configured to render the retention device 29 substantially ineffective until a substantial amount of the retention coating 31 has been biodegraded or otherwise removed.
The legs 6 can have mechanical interfaces 33, for example, a slot, snap, protrusion, latch, catch or combinations thereof. The interfaces 33 can be aligned so the interface on one leg 6 meets the interface 33 on the other leg 6 at the point where the legs 6 cross. The interfaces 33 can removably attach to each other.
Methods of Making
Other methods known to one having ordinary skill in the art can be used to manufacture the attachment device 2 and/or its elements. For example, manufacturing techniques include molding, machining, casting, forming (e.g., pressure forming), crimping, stamping, melting, screwing, gluing, welding, die cutting, laser cutting, electrical discharge machining (EDM), etching or combinations thereof.
Any elements, sub-assemblies, or the attachment device 2 as a whole after final assembly, can be coated by dip-coating or spray-coating methods known to one having ordinary skill in the art, utilizing materials such as PTFE (e.g., TEFLON® from E.I. du Pont de Nemours and Company, Wilmington, Del.), polyester (e.g., DACRON® from E.I. du Pont de Nemours and Company, Wilmington, Del.), gelatin, gel, other polymers or combinations thereof. One example of a method used to coat a medical device for vascular use is provided in U.S. Pat. No. 6,358,556 by Ding et al. and hereby incorporated by reference in its entirety. Time release coating methods known to one having ordinary skill in the art can also be used to delay the release of an agent in the coating. The coatings can be thrombogenic or anti-thrombogenic.
The attachment device 2, or any element thereof (e.g., the base 4) can be covered with a fabric, for example polyester (e.g., DACRON® from E.I. du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE (e.g., TEFLON® from E.I. du Pont de Nemours and Company, Wilmington, Del.), ePTFE, nylon, extruded collagen, gel, gelatin, silicone or combinations thereof. Methods of covering an implantable device with fabric are known to those having ordinary skill in the art, for example, sintering, spray coating, adhesion, loose covering, dipping or combinations thereof.
Methods of Using
The attachment device 2 can have a first configuration (e.g., the configuration shown in
The attachment device can substantially revert to the second configuration even when some permanent hysteresis deformation occurs and/or when a foreign object (e.g., a first and/or second mass) is obstructing the attachment device 2. When the attachment device 2 has the first configuration, one or both legs 6 can be rotated with respect to the base 4 (e.g., by rotating the base 4 around the base axis 12, one or both legs 6 splay or separate as they are torqued by the twisting or rotating around of the base).
As illustrated in
Heart valve assemblies disclosed by Griffin et al. in U.S. Pat. No. 6,241,765, by Lane in U.S. Pat. No. 6,371,983 and by Ritz in U.S. Pat. No. 5,976,183, both of which are hereby incorporated in their entireties, can be placed with the use of the device of the present invention. Other heart valve assemblies that can be used include, for example, the Advantage Bileaflet heart valve, Parallel valve, Freestyle stentless aortic valve, Hancock Porcine heart valve, Hancock apical left ventricular connector model 174A, Hancock valved conduit models 100, 105, 150, Hall Medtronic heart valve, Hall Medtronic valved conduit, MOSAIC® heart valve and Intact porcine tissue valve (by Medtronic, Inc. Minneapolis, Minn.); Angelini Lamina-flo valve (by Cardio Carbon Company, Ltd., England); Bjork-Shiley single-disk, monostrut and caged-disk valves (Shiley, Inc., now-defunct, previously of CA); Wada-Cutter valve and Chitra Cooley-Cutter valve (by Cutter Biomedical Corp., San Diego, Calif.); Angioflex trileaflet polyurethane valve (by Abiomed, Inc., Danvers, Mass.); ATS AP Series heart valve and ATS Standard heart valve (by ATS Medical, Inc., Minneapolis, Minn.); ANNULOFLO® annuloplasty ring, ANNUFLEX® annuloplasty ring, CARBSEAL® valved conduit, ORBIS® Universal aortic and mitral valve, pediatric/small adult valve, R series valve, SUMIT® mitral valve, TOP HAT® aortic valve, OPTIFORM® mitral valve, MITROFLOW SYNERGY® PC stented aortic pericardial bioprosthesis and the SYNERGY® ST stented aortic and mitral porcine bioprosthesis (by CarboMedics, Inc., Austin, Tex.); ON-X® prosthetic heart valve (by MCRI®, LLC, Austin, Tex.); Starr-Edwards SILASTIC® ball valve, Starr-Edwards 1000, Starr-Edwards 1200, Starr-Edwards 1260, Starr-Edwards 2400, Starr-Edwards 6300, Starr-Edwards 6500, Starr-Edwards 6520, Carpentier-Edwards porcine tissue valve, Carpentier-Edwards pericardial prosthesis, Carpentier-Edwards supra-annular valve, Carpentier-Edwards annuloplasty rings, Duromedics valve and PERIMOUNT® heart valve (by Edwards Lifesciences Corp., Irvine, Calif.); Cross-Jones Lenticular disc valve (by Pemco, Inc.); Tissuemed stented porcine valve (by Tissuemed, Ltd., Leeds, England); Tekna valve (by Baxter Healthcare, Corp., Deerfield, Ill.); Komp-01 mitral retainer ring (by Jyros Medical Ltd., London, England); SJM® Masters Series mechanical heart valve, SJM® Masters Series aortic valved graft prosthesis, ST. JUDE MEDICAL® mechanical heart valves, ST. JUDE MEDICAL® mechanical heart valve Hemodynamic Plus (HP) series, SJM REGENT® valve, TORONTO SPV® (Stentless Porcine Valve) valve, SJM BIOCOR® valve and SJM EPIC® valve (St. Jude Medical, Inc., St. Paul, Minn.); Sorin Bicarbon, Sorin Carbocast, Sorin Carboseal Conduit, Sorin Pericarbon and Sorin Pericarbon Stentless (by Snia S.p.A., Italy). The attachment devices of the present invention may be deployed to implant these various devices in the supra-annular position, or infrannular, depending on the geometry and preferred placement of a particular device. Similarly, it may be advantageous to use the attachment devices 2 of the present invention to secure a sewing ring, or first prosthesis by placing them horizontally or vertically within or around the annulus of such ring, prior to placing a second prosthesis including a valve structure, as provided in U.S. application Ser. No. 10/646,639 filed, 22 Aug. 2003, hereby incorporated by reference in its entirety.
The attachment device 2 can be removed and redeployed at any stage of deployment supra, for example, if the surgeon is unsatisfied with the position of the attachment device 2, or if the prosthesis need replacing or “redoing” at a point in the future. If the attachment device 2 has a retention device 29, when the retention coating 31 sufficiently biodegrades or is otherwise removed, the retention devices 29 will become exposed and can substantially prevent the removal of the attachment device 2 from the deployment site. Removal may still be achieved however, by apply sufficient force (by a tool or other device) to overcome the strength of the secondary retention element.
The attachment device 2 can be removed from the second mass 70 and/or the first mass 68, when applicable, by reversing the steps of the deployment methods supra.
A driver shaft 100 can have a driver handle 102 at a first end and grips 104 at a second end. The pivot 90 can have a longitudinal channel 106. The driver shaft 100 can pass through the longitudinal channel 106 and/or be rotatably mounted to a case (not shown) fixed to a lever 86 or 88. The grips 104 can be releasably attached to the attachment device 2. The attachment device 2 can be rotated about the longitudinal axis 2 by releasing the pads 94 and rotating, as shown by arrows 108, the driver handle.
The top part 110 and/or the bottom part 112 can have grooves 116 sized to fit the base 4 and a portion of one or more legs 6 when the attachment device 2 has the first configuration. The attachment device 2 can be forced to have the first configuration and be loaded into the tool 84, as shown by arrow 118. The top part 110 can be attached to the bottom part 112 with the attachment device 2 seated (not shown) in the grooves 116.
The attachment device 2 can be placed at a desired deployment site by the tool 84. The device 2 can be deployed from the tool 84 by removing the top part 110 from the bottom part 112, and removing the tool 84 from the deployment site.
The ends of the tools 84 shown in
Additional disclosure is included in U.S. patent application Ser. Nos. 10/327,821 and 10/646,639, filed 20 Dec. 2002 and 22 Aug. 2003, respectively, which are hereby incorporated by reference in their entireties. It is apparent to one skilled in the art that various changes and modifications can be made to this disclosure, and equivalents employed, without departing from the spirit and scope of the invention. Elements shown with any embodiment are exemplary for the specific embodiment and can be used on other embodiments within this disclosure.
Number | Name | Date | Kind |
---|---|---|---|
3143742 | Cromie | Aug 1964 | A |
3371352 | Siposs et al. | Mar 1968 | A |
3464065 | Cromie | Sep 1969 | A |
4345601 | Fukuda | Aug 1982 | A |
4485816 | Krumme | Dec 1984 | A |
4548202 | Duncan | Oct 1985 | A |
4595007 | Mericle | Jun 1986 | A |
4665906 | Jervis | May 1987 | A |
4705516 | Barone et al. | Nov 1987 | A |
4932955 | Merz et al. | Jun 1990 | A |
5002562 | Oberlander | Mar 1991 | A |
5002563 | Pyka et al. | Mar 1991 | A |
5007921 | Brown | Apr 1991 | A |
5026391 | McQueen et al. | Jun 1991 | A |
5156609 | Nakao et al. | Oct 1992 | A |
5171252 | Friedland | Dec 1992 | A |
5192303 | Gatturna et al. | Mar 1993 | A |
5246443 | Mai | Sep 1993 | A |
5282829 | Hermes | Feb 1994 | A |
5364406 | Sewell, Jr. | Nov 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5464416 | Steckel | Nov 1995 | A |
5573543 | Akopov et al. | Nov 1996 | A |
5618311 | Gryskiewicz | Apr 1997 | A |
5660188 | Groiso | Aug 1997 | A |
5716370 | Williamson et al. | Feb 1998 | A |
5720755 | Dakov | Feb 1998 | A |
5725554 | Simon et al. | Mar 1998 | A |
5779707 | Bertholet et al. | Jul 1998 | A |
5785713 | Jobe | Jul 1998 | A |
5860992 | Daniel et al. | Jan 1999 | A |
5891160 | Williamson, IV et al. | Apr 1999 | A |
5902310 | Foerster et al. | May 1999 | A |
5908428 | Scirica et al. | Jun 1999 | A |
5921997 | Fogelberg et al. | Jul 1999 | A |
5941890 | Voegele et al. | Aug 1999 | A |
5957940 | Tanner et al. | Sep 1999 | A |
5976183 | Ritz | Nov 1999 | A |
6001110 | Adams | Dec 1999 | A |
6042607 | Williamson, IV et al. | Mar 2000 | A |
6059787 | Allen | May 2000 | A |
6074401 | Gardiner et al. | Jun 2000 | A |
6113611 | Allen et al. | Sep 2000 | A |
6149658 | Gardiner et al. | Nov 2000 | A |
6152935 | Kammerer et al. | Nov 2000 | A |
6162233 | Williamson et al. | Dec 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6203553 | Robertson et al. | Mar 2001 | B1 |
6220248 | Voegele et al. | Apr 2001 | B1 |
6241765 | Griffin et al. | Jun 2001 | B1 |
6248117 | Blatter | Jun 2001 | B1 |
6334446 | Beyar | Jan 2002 | B1 |
6348054 | Allen | Feb 2002 | B1 |
6358556 | Ding et al. | Mar 2002 | B1 |
6371983 | Lane | Apr 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6432064 | Hibner et al. | Aug 2002 | B1 |
6447524 | Knodel et al. | Sep 2002 | B1 |
6514265 | Ho et al. | Feb 2003 | B2 |
6551332 | Nguyen et al. | Apr 2003 | B1 |
6607542 | Wild | Aug 2003 | B1 |
6626899 | Houser et al. | Sep 2003 | B2 |
6638297 | Huitema | Oct 2003 | B1 |
6641593 | Schaller et al. | Nov 2003 | B1 |
6676671 | Robertson et al. | Jan 2004 | B2 |
6702826 | Liddicoat et al. | Mar 2004 | B2 |
20020035361 | Houser et al. | Mar 2002 | A1 |
20020042621 | Liddicoat et al. | Apr 2002 | A1 |
20020058967 | Jervis | May 2002 | A1 |
20020173793 | Allen | Nov 2002 | A1 |
20030045902 | Weadock | Mar 2003 | A1 |
20030208211 | Kortenbach | Nov 2003 | A1 |
20040193191 | Starksen et al. | Sep 2004 | A1 |
20050107871 | Realyvasquez et al. | May 2005 | A1 |
Number | Date | Country |
---|---|---|
19711288 | Oct 1998 | DE |
0 552 433 | Nov 1992 | EP |
0 552 433 | Nov 1992 | EP |
0 580 994 | Jun 1993 | EP |
0 580 994 | Jun 1993 | EP |
0641546 | Mar 1995 | EP |
0826340 | Mar 1998 | EP |
320731 | Apr 1902 | FR |
2 359 024 | Aug 2001 | GB |
WO 9600820 | Mar 1996 | WO |
WO 9608208 | Mar 1996 | WO |
WO 9616603 | Jun 1996 | WO |
9739688 | Oct 1997 | WO |
9858591 | Dec 1998 | WO |
WO 0110310 | Feb 2001 | WO |
WO 0158363 | Aug 2001 | WO |
WO 02080779 | Oct 2002 | WO |
WO 03003930 | Jan 2003 | WO |
WO 03053289 | Jul 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20050080454 A1 | Apr 2005 | US |